Medical - Devices
Compare Stocks
2 / 10Stock Comparison
BDMD vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
BDMD vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Biotechnology |
| Market Cap | $68M | $1712.35T |
| Revenue (TTM) | $37M | $0.00 |
| Net Income (TTM) | $12M | $-168M |
| Gross Margin | 88.2% | — |
| Operating Margin | 41.4% | — |
| Forward P/E | 3.8x | — |
| Total Debt | $21M | $22M |
| Cash & Equiv. | $3M | $194M |
BDMD vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 21 | May 26 | Return |
|---|---|---|---|
| Baird Medical Inves… (BDMD) | 100 | 18.9 | -81.1% |
| DBV Technologies S.… (DBVT) | 100 | 124.9 | +24.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BDMD vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BDMD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.15
- Rev growth 17.7%, EPS growth 19.5%, 3Y rev CAGR 10.1%
- -80.8% 10Y total return vs DBVT's -87.0%
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs BDMD's -65.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 17.7% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 33.6% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 1.15 vs DBVT's 1.26 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +110.4% vs BDMD's -65.2% | |
| Efficiency (ROA) | 18.5% ROA vs DBVT's -89.0% |
BDMD vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
BDMD and DBVT operate at a comparable scale, with $37M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $37M | $0 |
| EBITDAEarnings before interest/tax | — | -$112M |
| Net IncomeAfter-tax profit | — | -$168M |
| Free Cash FlowCash after capex | — | -$151M |
| Gross MarginGross profit ÷ Revenue | +88.2% | — |
| Operating MarginEBIT ÷ Revenue | +41.4% | — |
| Net MarginNet income ÷ Revenue | +33.6% | — |
| FCF MarginFCF ÷ Revenue | -24.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +91.5% |
Valuation Metrics
DBVT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $68M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $86M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | 3.80x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 5.13x | — |
| Price / SalesMarket cap ÷ Revenue | 1.84x | — |
| Price / BookPrice ÷ Book value/share | 1.20x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
BDMD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
BDMD delivers a 33.0% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to BDMD's 0.53x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs BDMD's 2/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +33.0% | -130.2% |
| ROA (TTM)Return on assets | +18.5% | -89.0% |
| ROICReturn on invested capital | +22.6% | — |
| ROCEReturn on capital employed | +37.8% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.53x | 0.13x |
| Net DebtTotal debt minus cash | $18M | -$172M |
| Cash & Equiv.Liquid assets | $3M | $194M |
| Total DebtShort + long-term debt | $21M | $22M |
| Interest CoverageEBIT ÷ Interest expense | 26.55x | -189.82x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $1,923 for BDMD. Over the past 12 months, DBVT leads with a +110.4% total return vs BDMD's -65.2%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs BDMD's -43.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +38.8% | +4.9% |
| 1-Year ReturnPast 12 months | -65.2% | +110.4% |
| 3-Year ReturnCumulative with dividends | -81.9% | +19.7% |
| 5-Year ReturnCumulative with dividends | -80.8% | -69.1% |
| 10-Year ReturnCumulative with dividends | -80.8% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -43.4% | +6.2% |
Risk & Volatility
Evenly matched — BDMD and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
BDMD is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs BDMD's 25.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.15x | 1.26x |
| 52-Week HighHighest price in past year | $7.26 | $26.18 |
| 52-Week LowLowest price in past year | $0.76 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +25.6% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 47.5 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 960K | 252K |
Analyst Outlook
BDMD leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
DBVT leads in 2 of 6 categories (Valuation Metrics, Total Returns). BDMD leads in 2 (Profitability & Efficiency, Analyst Outlook). 1 tied.
BDMD vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BDMD or DBVT a better buy right now?
Baird Medical Investment Holdings Limited (BDMD) offers the better valuation at 3.
8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BDMD or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -80. 8% for Baird Medical Investment Holdings Limited (BDMD). Over 10 years, the gap is even starker: BDMD returned -80. 8% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BDMD or DBVT?
By beta (market sensitivity over 5 years), Baird Medical Investment Holdings Limited (BDMD) is the lower-risk stock at 1.
15β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 10% more volatile than BDMD relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 53% for Baird Medical Investment Holdings Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — BDMD or DBVT?
On earnings-per-share growth, the picture is similar: Baird Medical Investment Holdings Limited grew EPS 19.
5% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BDMD or DBVT?
Baird Medical Investment Holdings Limited (BDMD) is the more profitable company, earning 33.
6% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 33. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDMD leads at 41. 4% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — BDMD leads at 88. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BDMD or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BDMD or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Baird Medical Investment Holdings Limited (BDMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
15)). Both have compounded well over 10 years (BDMD: -80. 8%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BDMD and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BDMD is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.